Get started
NEKTAR THERAPEUTICS COM STK USD0.0001NEKTAR THERAPEUTICS COM STK USD0.0001NEKTAR THERAPEUTICS COM STK USD0.0001

NEKTAR THERAPEUTICS COM STK USD0.0001

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0UNL chart


Full chart

0UNL upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪171.23 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.8370 USD
Net income (FY)
‪−276.06 M‬ USD
Revenue (FY)
‪90.12 M‬ USD
Shares float
‪177.51 M‬
Beta (1Y)
3.02

Employees


Employees (FY)
137
Change (1Y)
−79 −36.57%
Revenue / Employee (1Y)
‪657.82 K‬ USD
Net income / Employee (1Y)
‪−2.02 M‬ USD

About Nektar Therapeutics


Sector
Health Technology
CEO
Howard W. Robin
Headquarters
San Francisco
Website
nektar.com
Founded
1990
FIGI
BBG00LG7G039
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0UNL news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0UNL is 0.9400 USD — it has decreased by −6.00% in the past 24 hours. Watch NEKTAR THERAPEUTICS COM STK USD0.0001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange NEKTAR THERAPEUTICS COM STK USD0.0001 stocks are traded under the ticker 0UNL.
0UNL stock has fallen by −6.00% compared to the previous week, the month change is a −11.32% fall, over the last year NEKTAR THERAPEUTICS COM STK USD0.0001 has showed a 100.00% increase.
We've gathered analysts' opinions on NEKTAR THERAPEUTICS COM STK USD0.0001 future price: according to them, 0UNL price has a max estimate of 7.00 USD and a min estimate of 1.30 USD. Watch 0UNL chart and read a more detailed NEKTAR THERAPEUTICS COM STK USD0.0001 stock forecast: see what analysts think of NEKTAR THERAPEUTICS COM STK USD0.0001 and suggest that you do with its stocks.
0UNL reached its all-time high on Sep 5, 2018 with the price of 68.4900 USD, and its all-time low was 0.4350 USD and was reached on Nov 13, 2023. View more price dynamics on 0UNL chart.
See other stocks reaching their highest and lowest prices.
0UNL stock is 8.70% volatile and has beta coefficient of 3.02. Track NEKTAR THERAPEUTICS COM STK USD0.0001 stock price on the chart and check out the list of the most volatile stocks — is NEKTAR THERAPEUTICS COM STK USD0.0001 there?
Yes, you can track NEKTAR THERAPEUTICS COM STK USD0.0001 financials in yearly and quarterly reports right on TradingView.
NEKTAR THERAPEUTICS COM STK USD0.0001 is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
0UNL earnings for the last quarter are −0.18 USD per share, whereas the estimation was −0.20 USD resulting in a 9.55% surprise. The estimated earnings for the next quarter are −0.13 USD per share. See more details about NEKTAR THERAPEUTICS COM STK USD0.0001 earnings.
NEKTAR THERAPEUTICS COM STK USD0.0001 revenue for the last quarter amounts to ‪24.12 M‬ USD, despite the estimated figure of ‪19.18 M‬ USD. In the next quarter, revenue is expected to reach ‪36.60 M‬ USD.
0UNL net income for the last quarter is ‪−37.06 M‬ USD, while the quarter before that showed ‪−52.36 M‬ USD of net income which accounts for 29.23% change. Track more NEKTAR THERAPEUTICS COM STK USD0.0001 financial stats to get the full picture.
No, 0UNL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 137.00 employees. See our rating of the largest employees — is NEKTAR THERAPEUTICS COM STK USD0.0001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NEKTAR THERAPEUTICS COM STK USD0.0001 EBITDA is ‪−130.19 M‬ USD, and current EBITDA margin is −143.82%. See more stats in NEKTAR THERAPEUTICS COM STK USD0.0001 financial statements.
Like other stocks, 0UNL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEKTAR THERAPEUTICS COM STK USD0.0001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NEKTAR THERAPEUTICS COM STK USD0.0001 technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NEKTAR THERAPEUTICS COM STK USD0.0001 stock shows the sell signal. See more of NEKTAR THERAPEUTICS COM STK USD0.0001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.